Monoclonal antibodies (Mabs) conjugated to toxins or ... Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in ...

Type II: GA101 is a third-generation, fully humanized, glycoengineered Fc region resulting in a much higher antibody-dependent cellular cytotoxicity level. Anti-CD22 Monoclonal Antibodies ...

Catalent has announced that Triphase Accelerator Corporation will obtain worldwide rights to further develop its proprietary ...

Moxetumomab pasudotox is composed of a binding portion of an anti-CD22 antibody fused to a toxin. The drug binds to CD22, a protein that is overexpressed on the surface of HCL cells, and then ...

Type II: GA101 is a third-generation, fully humanized, glycoengineered Fc region resulting in a much higher antibody-dependent cellular cytotoxicity level. Anti-CD22 Monoclonal Antibodies ...